You are here

  • Home
  • Archive
  • Volume 12, Issue 7
  • Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model

Article info

Article menu
Immune cell therapies and immune cell engineering
Original research
Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model

Authors

  • Inés Sánchez-Moreno Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Aritz Lasarte-Cia Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Celia Martín-Otal Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Noelia Casares Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Flor Navarro Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Marta Gorraiz Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Patricia Sarrión Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Sandra Hervas-Stubbs Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, SpainCancer Center Universidad de Navarra (CCUN), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Lorea Jordana Hemato-Oncology Program, Centre for Applied Medical Research (CIMA), University of Navarra, IdiSNA, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Juan Roberto Rodriguez-Madoz Cancer Center Universidad de Navarra (CCUN), Pamplona, SpainHemato-Oncology Program, Centre for Applied Medical Research (CIMA), University of Navarra, IdiSNA, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Jesús San Miguel Cancer Center Universidad de Navarra (CCUN), Pamplona, SpainHematology and Cell Therapy Department, Clínica Universidad de Navarra, (CUN), Pamplona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Felipe Prosper Cancer Center Universidad de Navarra (CCUN), Pamplona, SpainHemato-Oncology Program, Centre for Applied Medical Research (CIMA), University of Navarra, IdiSNA, Pamplona, SpainHematology and Cell Therapy Department, Clínica Universidad de Navarra, (CUN), Pamplona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Juan Jose Lasarte Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, SpainCancer Center Universidad de Navarra (CCUN), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Teresa Lozano Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, SpainCancer Center Universidad de Navarra (CCUN), Pamplona, Spain PubMed articlesGoogle scholar articles

Citation

Sánchez-Moreno I, Lasarte-Cia A, Martín-Otal C, et al
Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model
Journal for ImmunoTherapy of Cancer 2024;12:e008572. doi: 10.1136/jitc-2023-008572
Online issue publication 
July 01, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.